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lar disease the cost estimates included only initial acute
care. In another on stroke prevention, also by us, costs in-
cluded subsequent care for up to 15 years after the initial
event. This difference can substantially influence the re-
sulting cost-effectiveness ratios. Both approaches are cor-
rect for their purpose, but the difference would be un-
known to the decision maker viewing the league table.
League tables mislead decision makers into feeling in-
formed without realizing how little is known. These
problems cannot be cured by methodological guidelines.
Pharmacoeconomic researchers should resist creating
league tables and thereby providing both too little and
too much information to decision makers.
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The present reformed health care system is driven mainly
by cost containment. This poses some challenges to
health care practitioners in regard to the decision on
which therapeutic agents (drugs) get added or deleted
from the formulary. The challenge is in utilizing pharrna-
coeconomic tools and outcomes (clinical and humanistic)
research to arrive at a formulary that provides the patient
with effective drug therapy. The literature suggests that
effective drug therapy improves clinical outcomes and en-
hances patients' quality of life.
OBJECTIVES: The primary objective of this pilot study
was to assess the use or extent of use of pharmacoeco-
nomic methods and clinical and humanistic outcomes by
pharmacists (serving on a pharmacy and therapeutic
[P&T) committee) in making formulary decisions. The
secondary objective of the study was to examine the asso-
ciation between training in pharmacoeconomics and out-
comes research, and the application of the principles and
methods of these two disciplines.
METHODS: A 3D-item survey instrument was adminis-
tered to a convenient sample of 17 pharmacists. The in-
strument was designed to collect data on the demograph-
ics, pharmacoeconomics and outcomes research training,
and application of pharmacoeconomic tools and out-
comes research to formulary decision-making.
RESULTS: The percentage of respondents who indicated
using cost-minimization, cost-effectiveness, cost-benefit,
cost-utility, onset of action of drug/therapy, and recur-
rence of symptoms in formulary decision-making was
82.4%, 58.8%, 70.6%, 29.4%, 64%, and 76.5%, re-
spectively. There were a number significant correlations
between the application of pharmacoeconomic methods
and outcome measures (clinical and humanistic). Gener-
ally, there was no significant association between formal
training and application of the pharmacoeconomic meth-
ods and outcomes research.
CONCLUSION: The study suggests that pharmacists on
Abstracts
P&T committees generally apply pharmacoeconomic
methods and outcomes research in making formulary de-
cisions.
P"DI4
VOX POPULI: STATED PREFERENCES FOR
PHARMACEUTICAL INNOVATIONS
Bingham MF',Johnson FR', Bell 12
'T riangle Economic Research, Durham, NC, USA;
21ndependent Consultant
This paper outlines a decision model for evaluating the
effect of information regarding toxicity, efficacy, cost,
and alternative treatments on anticipated adoption rates
of developmental compounds.
METHODS: The paper discusses the relationship be-
tween multiattribute utility theory and people's prefer-
ences for health outcomes. Health outcomes arising from
pharmaceutical interventions are viewed as multiattribute
commodities. A method for reliable quantification of
health-state preferences is described. This procedure re-
quires estimating utility weights from stated-preference
(SP) data. By including health cost as an SP attribute,
marginal utilities are converted to marginal dollar values
to explicitly account for cost in determining market
share. Additionally, SP allows for a nonlinear association
between willingness to pay and health states reflecting the
diminishing marginal utility of health. Furthermore, this
technique permits estimating weights for combined
health states. A recent SP design for eliciting respondent
trade-offs among episode duration, symptom, daily-activ-
ity limitations, and cost is presented. Additionally, vari-
ous utility specifications and simplifying assumptions are
described. Finally, a rule for simulating aggregate choice
behavior is presented. The prediction rule employed
draws upon random utility theory. This method ad-
dresses the probabilistic nature of choices by including a
residual term to represent the effect of unobserved factors
on utility. A numerical example demonstrates the capa-
bility of the decision model. In this example, a general,
preference-based form for health-related utility facilitates
direct estimation of health attribute utility weights arising
from pharmaceutical product choice. This example dem-
onstrates how the model evaluates the impact of cost,
outcomes, and competition on anticipated drug adoption
rates.
CONCLUSION: Integrating stated-preference data, ran-
dom-utility modeling, and cost-utility analysis provides a
reliable way to describe preferences and predict choice
behavior. This capability provides important information
for developmental pharmaceutical product marketing
decisions.
